Clinical Trial Search

Primary: Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment. — 77.2; 126.7; 81.0 pg/mL — p=< 0.01

Primary: Monocular Photopic Best Corrected Distance Visual Acuity (5 m) — 15; 5; 9; 8 subjects

Primary: Length of Time Required for Successful Advancement of Endotracheal Tube Into Trachea — 6.36; 8.81 seconds

Primary: Post Operative Pain — 3.18; 2.27; 2.20; 1.39 score on a scale — p=0.083

Primary: Left Ventricular Strain — 0.2; 0.4 Percent change in circumference — p=0.5867

Primary: Progression-free Survival Rate at Four Months (PFS4) — 27.3; 15.8; 26.1 percentage of participants

Primary: Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden — -1.22; -0.98 ulcers — p=0.70

Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score Following First Treatment Cycle — -12.46; -13.99; -3.93 Units on a scale…

Primary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI) — 0.036; 0.017; -0.003 Liter

Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint) — -48.264; -40.640; 3.190 Percent change — p=<0.001

Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001

Primary: Overall Response Rate, as Per the IWCLL 2008 Response Criteria — 1; 13; 14 Participants

Primary: The Percentage of Eyes Achieving the Target of Monocular Uncorrected Visual Acuity of 20/40 or Better — 324 Eyes

Primary: Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment — 0…

Primary: Knee Injury and Osteoarthritis Outcome Score — 16.71; 10.93; 14.00; 10.47 score on a scale